GlassScriptPhysician profile
Paul H Dang
NPI 1407884760
$3,451.81
in general payments reported to CMS, 2019-2025
27 companies · $916 in 2025
The $916 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,594 · 2020: $13.18 · 2022: $98.78 · 2024: $830 · 2025: $916.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,745.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $498.07 | 2019-2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $396.58 | 2024-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Novo Nordisk INC | $360.29 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $359.50 | 2019-2025 | Evenity, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $335.07 | 2019-2024 | Airsupra |
| Pfizer INC. | $209.55 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $192.95 | 2019-2025 | Jardiance, Gilotrif |
| Amarin Pharma, INC. | $161.42 | 2019 | |
| Janssen Pharmaceuticals, INC | $150.44 | 2019 | |
| Medtronic, INC. | $134.48 | 2024 | Endurant Iis |
| Abbvie INC. | $103.31 | 2019-2024 | |
| Astellas Pharma US INC | $88.19 | 2019 | |
| Glaxosmithkline, LLC. | $84.56 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.03 | 2025 | |
| Sanofi-Aventis U.S. LLC | $53.39 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $27.83 | 2019 | |
| Sunovion Pharmaceuticals INC. | $27.23 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.04 | 2019 | |
| Acadia Pharmaceuticals INC | $27.02 | 2025 | Nuplazid |
| Antares Pharma, INC. | $24.24 | 2025 | Xyosted |
| Iovance Biotherapeutics, INC. | $23.37 | 2025 | Amtagvi |
| Xeris Pharmaceuticals, INC. | $23.03 | 2025 | Gvoke Hypopen |
| Bausch Health US, LLC | $15.42 | 2019 | |
| Zyla Life Sciences, INC. | $14.89 | 2019 | |
| Mylan Specialty L.P. | $14.63 | 2019 | |
| Allergan, INC. | $13.25 | 2019 | |
| Merck Sharp & Dohme LLC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Dang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.